English (UK)
中文版Qin Li
A private pharmaceutical company,headquartered in Beijing,focus on the research, development,manufacture and marketing of drug products for the treatment of organ fibrosis diseases and other related diseases.
Beijing Continent Pharmaceutical Co., Ltd.
Associate Director,Business DevelopmentAllen Li
Pregene is a world-leading cell and gene therapy company. Pregene is committed to develop innovative gene and cell therapy technologies and create reliable products from continued innovation and R&D. And pregene can provide CDMO service.
Shenzhen Pregene Biopharma Co., ltd
BD DirectorJian Li
HitGen is a rapidly growing biotech company with headquarter and main research facility based in Chengdu, China and with a subsidiary in the United States. HitGen has established an industry-leading platform for early-stage drug discovery research centred on the design, synthesis and screening of DNA encoded chemical libraries (DELs).
HitGen’s DELs cover more than 500 billion novel, diverse molecules from different types of chemical libraries, including drug-like/lead-like small molecules, macrocycles, molecules with electrophiles (co-valent binding), protein degraders, molecular fragments, etc,. These compounds are members of DELs synthesized from many hundreds of distinct chemical scaffolds, designed with tractable chemistry, and yielded proven results for the discovery of small molecule leads against precedented and unprecedented classes of biological targets.
In order to support the exploitation of DEL screening output, HitGen has also built structural biology, medicinal chemistry, in vitro and in vivo biology capabilities to support our partner’s drug discovery research projects.
HitGen is collaborating with pharmaceutical, biotech, and chemical companies, foundations and research institutes in North America, Europe, Asia and Africa to discover and develop approaches for novel medicines and other solutions.
HitGen's novel small molecule inhibitor for Class I/IIb HDAC, HG146, is in Phase I clinical trials for Multiple Myeloma. Another new class of second generation TRK/ROS1 inhibitor, HG030, has obtained clinical approval from NMPA. HitGen’s preclinical portfolio includes small molecule IL17A inhibitor and non-nucleoside STING agonist.
http://chinabio-partnering.com/events/CBPF2020/en/home
HitGen’s DELs cover more than 500 billion novel, diverse molecules from different types of chemical libraries, including drug-like/lead-like small molecules, macrocycles, molecules with electrophiles (co-valent binding), protein degraders, molecular fragments, etc,. These compounds are members of DELs synthesized from many hundreds of distinct chemical scaffolds, designed with tractable chemistry, and yielded proven results for the discovery of small molecule leads against precedented and unprecedented classes of biological targets.
In order to support the exploitation of DEL screening output, HitGen has also built structural biology, medicinal chemistry, in vitro and in vivo biology capabilities to support our partner’s drug discovery research projects.
HitGen is collaborating with pharmaceutical, biotech, and chemical companies, foundations and research institutes in North America, Europe, Asia and Africa to discover and develop approaches for novel medicines and other solutions.
HitGen's novel small molecule inhibitor for Class I/IIb HDAC, HG146, is in Phase I clinical trials for Multiple Myeloma. Another new class of second generation TRK/ROS1 inhibitor, HG030, has obtained clinical approval from NMPA. HitGen’s preclinical portfolio includes small molecule IL17A inhibitor and non-nucleoside STING agonist.
http://chinabio-partnering.com/events/CBPF2020/en/home
HitGen Inc.
BD ConsultantMs Sarai LI
Listed in China Growth Board, WolwoPharma is the biggest allergen drug manufacturer in China
and the largest allergen preparation supplier in Asia.
and the largest allergen preparation supplier in Asia.
Responsive Web Design powered by 